UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.

                                  June 7, 2005
                Date of Report (Date of Earliest Event Reported)


                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)


                         Commission File Number: 0-31905


                Utah                                   59-2780520
       (State of Incorporation)                (I.R.S. Employer I.D. No)


                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)


                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)


      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
<PAGE>

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Consulting Agreement with Dr. Arthur Sytkowski

      On June 7, 2005, the Registrant  entered into a Consulting  Agreement (the
"Agreement")  with  Dr.  Arthur  Sytkowski,  the  Director  of the  Beth  Israel
Deaconess Medical Center, a Massachusetts  nonprofit corporation ("Beth Israel")
to consult on the  development  of a new,  more potent and longer acting form of
the anemia drug Erythropoietin ("EPO").

      EPO is a  glycoprotein  naturally  made by the body to stimulate red blood
cell production; the currently marketed forms are manufactured using recombinant
DNA technology and are used to treat anemia or low blood cell count. As reported
on April 8, 2005, Beth Israel has granted the Registrant an exclusive license to
United  States and foreign  patents  related to certain  forms of EPO (the "Beth
Israel license").  The Registrant has the right to develop, use, market and sell
products derived from the licensed patents.

      Under the  Consulting  Agreement,  Dr.  Sytkowski  has  agreed to  perform
certain  consulting  services,  including  advising on medical,  regulatory  and
patent issues, training personnel and providing assistance with EPO research and
development. In exchange for the services, the Registrant will pay Dr. Sytkowski
$10,000 a month for six months,  five annual incentive  payments of $25,000 each
and certain  milestone  payments linked to the  Registrant's  progress under the
Beth Israel  license in  developing  marketable  products  from the licensed EPO
technology.  The total of all  payments to Dr.  Sytkowski  under the  Agreement,
assuming all milestones are reached, is $310,000. The milestone payments will be
reduced - dollar for dollar - to the extent Dr. Sytkowski receives payments from
Beth Israel relating to the same milestone events under the Beth Israel license.

Item 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN OBLIGATION  UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

      (c)   Exhibits:

            10.1  Consulting  Services  Agreement  with Dr. Arthur J.  Sytkowski
                  dated June 7, 2005


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                              DNAPrint genomics, Inc.


                                              By: /s/ Richard Gabriel
                                                 -------------------------------
                                                 Richard Gabriel, President


                                       3
{"company-data": {"conformed-name": "DNAPRINT GENOMICS INC", "cik": "0001127354", "assigned-sic": "8731", "irs-number": "592780520", "state-of-incorporation": "UT", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-31905", "film-number": "05892648"}, "business-address": {"street1": "900 COCONUT AVE.", "city": "SARASOTA", "state": "FL", "zip": "34231", "phone": "9413663400"}, "mail-address": {"street1": "900 COCOANUT AVENUE", "street2": "NO SUITE", "city": "SARASOTA", "state": "FL", "zip": "34231"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.

                                  June 7, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

                Utah                                   59-2780520
       (State of Incorporation)                (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Consulting Agreement with Dr. Arthur Sytkowski

      On June 7, 2005, the Registrant  entered into a Consulting  Agreement (the
"Agreement")  with  Dr.  Arthur  Sytkowski,  the  Director  of the  Beth  Israel
Deaconess Medical Center, a Massachusetts  nonprofit corporation ("Beth Israel")
to consult on the  development  of a new,  more potent and longer acting form of
the anemia drug Erythropoietin ("EPO").

      EPO is a  glycoprotein  naturally  made by the body to stimulate red blood
cell production; the currently marketed forms are manufactured using recombinant
DNA technology and are used to treat anemia or low blood cell count. As reported
on April 8, 2005, Beth Israel has granted the Registrant an exclusive license to
United  States and foreign  patents  related to certain  forms of EPO (the "Beth
Israel license").  The Registrant has the right to develop, use, market and sell
products derived from the licensed patents.

      Under the  Consulting  Agreement,  Dr.  Sytkowski  has  agreed to  perform
certain  consulting  services,  including  advising on medical,  regulatory  and
patent issues, training personnel and providing assistance with EPO research and
development. In exchange for the services, the Registrant will pay Dr. Sytkowski
$10,000 a month for six months,  five annual incentive  payments of $25,000 each
and certain  milestone  payments linked to the  Registrant's  progress under the
Beth Israel  license in  developing  marketable  products  from the licensed EPO
technology.  The total of all  payments to Dr.  Sytkowski  under the  Agreement,
assuming all milestones are reached, is $310,000. The milestone payments will be
reduced - dollar for dollar - to the extent Dr. Sytkowski receives payments from
Beth Israel relating to the same milestone events under the Beth Israel license.

Item 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN OBLIGATION  UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

      (c)   Exhibits:

            10.1  Consulting  Services  Agreement  with Dr. Arthur J.  Sytkowski
                  dated June 7, 2005

                                       2
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                              DNAPrint genomics, Inc.

                                              By: /s/ Richard Gabriel
                                                 -------------------------------
                                                 Richard Gabriel, President

                                       3